Linezolid pharmacokinetics and pharmacodynamics in clinical treatment
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment
复制标题
DOI：
10.1093/jac/dkr072
复制
发表时间：
2011-05-01
影响因子：
5.2
通讯作者：
Dryden, Matthew S.
中科院分区：
文献类型：
--
作者：
Dryden, Matthew S.
利奈唑胺已被广泛用于治疗革兰氏阳性感染超过十年。在对大多数多重耐药革兰氏阳性细菌具有活性的抗生素中，它是独一无二的，因为它是一种具有100%生物利用度和广泛分发量的口服制剂。本综述研究了利奈唑胺在不同患者群体（肥胖、肠内喂养、肾衰竭、新生儿和儿科）和不同临床情况（脓毒症综合征、皮肤和软组织感染、糖尿病足感染、肺炎、骨骼和关节感染、中枢神经系统感染、眼睛感染和中性粒细胞减少性脓毒症）中使用的药代动力学数据。
Linezolid has been widely used in the treatment of Gram-positive infections for more than a decade. It is unique amongst antibiotics active against most multiply-resistant Gram-positive bacteria in that there is an oral preparation with 100% bioavailability and an extensive volume of distribution. This review examines pharmacokinetic data relating to linezolid use in different patient groups (obesity, enteral feeding, renal failure, neonates, and paediatrics) and in different clinical conditions (sepsis syndrome, skin and soft tissue infection, diabetic foot infection, pneumonia, bone and joint infection, infection of the central nervous system, eye infection, and neutropenic sepsis).